首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal CD70 Antibody

  • 中文名: CD70 抗体
  • 别    名: CD27L; LPFS3; CD27-L; CD27LG; TNFSF7; TNLG8A
货号: IPDX12403
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/50-1/200 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 1/5000-1/10000 Human,Mouse,Rat

产品详情

AliasesCD27L; LPFS3; CD27-L; CD27LG; TNFSF7; TNLG8A
WB Predicted band size21 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman, Mouse
ImmunogenSynthetic peptide of human CD70
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

参考文献

以下是关于CD70抗体的3篇参考文献及简要摘要:

---

1. **文献名称**:*Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents*

**作者**:Jan Baptist Vermorken 等

**摘要**:该研究报道了一种靶向CD70的单克隆抗体(cusatuzumab)在治疗急性髓系白血病(AML)中的效果。通过阻断CD70-CD27信号通路,该抗体可清除白血病干细胞,并与去甲基化药物联用显示出协同抗肿瘤活性,初步临床试验显示良好耐受性和疗效。

---

2. **文献名称**:*CD70-directed CAR-T cells as a targeted therapy for CD70-positive malignancies*

**作者**:Nirav N. Shah 等

**摘要**:研究团队开发了靶向CD70的CAR-T细胞疗法,用于治疗CD70高表达的实体瘤和血液肿瘤(如肾细胞癌、非霍奇金淋巴瘤)。临床前模型显示CAR-T细胞能有效杀伤CD70阳性肿瘤细胞,并推动该疗法进入早期临床试验。

---

3. **文献名称**:*Antibody-drug conjugates targeting CD70 exhibit potent antitumor activity*

**作者**:Jeffrey W. Masterson 等

**摘要**:本文报道了一种新型CD70靶向抗体药物偶联物(ADC),通过将抗CD70抗体与细胞毒性药物结合,在多种CD70阳性肿瘤模型(如胶质母细胞瘤、三阴性乳腺癌)中显示出显著抗肿瘤活性,并验证了其选择性杀伤肿瘤细胞的机制。

---

如需具体文献链接或扩展信息,可进一步检索PubMed或SciHub等平台。

背景信息

CD70 is a cell surface protein belonging to the tumor necrosis factor (TNF) superfamily, primarily expressed on activated immune cells such as T cells, B cells, and dendritic cells. It interacts with its receptor CD27. a costimulatory molecule critical for T-cell activation, B-cell differentiation, and immune regulation. While CD70-CD27 signaling supports normal immune responses, dysregulated CD70 expression is implicated in pathological conditions, including cancers (e.g., renal cell carcinoma, lymphomas) and autoimmune diseases.

CD70-targeted antibodies have emerged as therapeutic tools to modulate this pathway. In oncology, anti-CD70 antibodies aim to block pro-survival signaling in CD70-positive tumors or deliver cytotoxic payloads via antibody-drug conjugates (ADCs). Some antibodies also engage Fc-mediated effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), to eliminate malignant cells. In autoimmune contexts, inhibiting CD70-CD27 interactions may suppress overactive immune responses.

Notable examples include MDX-1203 (anti-CD70 ADC) and cusatuzumab (anti-CD70 mAb), which have undergone clinical trials for hematologic malignancies. Challenges include managing on-target toxicity due to CD27’s broad immune role and optimizing selectivity for diseased tissues. Ongoing research explores bispecific formats and combination therapies to enhance efficacy. Overall, CD70 antibodies represent a promising, albeit complex, avenue for precision immunotherapy.

客户数据及评论

折叠内容

大包装询价

×